Toyoshi Yanagihara - Search Results

Year	Number of Results
2011	1
2013	1
2014	1
2015	1
2017	12
2018	9
2019	7
2020	9
2021	16
2022	4
2023	3

1

Connective-Tissue Growth Factor Contributes to TGF-β1-induced Lung Fibrosis.

Yanagihara T, Tsubouchi K, Gholiof M, Chong SG, Lipson KE, Zhou Q, Scallan C, Upagupta C, Tikkanen J, Keshavjee S, Ask K, Kolb MRJ. Yanagihara T, et al. Am J Respir Cell Mol Biol. 2022 Mar;66(3):260-270. doi: 10.1165/rcmb.2020-0504OC. Am J Respir Cell Mol Biol. 2022. PMID: 34797990

2

Current models of pulmonary fibrosis for future drug discovery efforts.

Yanagihara T, Chong SG, Vierhout M, Hirota JA, Ask K, Kolb M. Yanagihara T, et al. Expert Opin Drug Discov. 2020 Aug;15(8):931-941. doi: 10.1080/17460441.2020.1755252. Epub 2020 May 12. Expert Opin Drug Discov. 2020. PMID: 32396021 Review.

3

Macitentan reduces progression of TGF-β1-induced pulmonary fibrosis and pulmonary hypertension.

Bellaye PS, Yanagihara T, Granton E, Sato S, Shimbori C, Upagupta C, Imani J, Hambly N, Ask K, Gauldie J, Iglarz M, Kolb M. Bellaye PS, et al. Among authors: yanagihara t. Eur Respir J. 2018 Aug 30;52(2):1701857. doi: 10.1183/13993003.01857-2017. Print 2018 Aug. Eur Respir J. 2018. PMID: 29976656 Free article.

4

Demystifying morphomolecular alterations of vasculature in interstitial lung diseases.

Yanagihara T, Jones KD. Yanagihara T, et al. Eur Respir J. 2020 Mar 12;55(3):1902446. doi: 10.1183/13993003.02446-2019. Print 2020 Mar. Eur Respir J. 2020. PMID: 32165424 Free article. No abstract available.

5

Tacrolimus Treatment for Post-COVID-19 Interstitial Lung Disease.

Ohgushi M, Ogo N, Yanagihara T, Harada Y, Sumida K, Egashira A, Asoh T, Maeyama T, Yoshizawa S. Ohgushi M, et al. Among authors: yanagihara t. Intern Med. 2022 Feb 15;61(4):585-589. doi: 10.2169/internalmedicine.7971-21. Epub 2021 Dec 4. Intern Med. 2022. PMID: 34866097 Free PMC article.

6

Molecular breath analysis for IPF: Can we make a few breaths count?

Yanagihara T, Kolb M. Yanagihara T, et al. Respirology. 2019 May;24(5):404-405. doi: 10.1111/resp.13503. Epub 2019 Feb 12. Respirology. 2019. PMID: 30747465 Free article. No abstract available.

7

Treatment of idiopathic pulmonary fibrosis with Nintedanib: an update.

Wongkarnjana A, Yanagihara T, Kolb MR. Wongkarnjana A, et al. Among authors: yanagihara t. Expert Rev Respir Med. 2019 Dec;13(12):1139-1146. doi: 10.1080/17476348.2019.1673733. Epub 2019 Oct 9. Expert Rev Respir Med. 2019. PMID: 31564185 Review.

8

What have we learned from basic science studies on idiopathic pulmonary fibrosis?

Yanagihara T, Sato S, Upagupta C, Kolb M. Yanagihara T, et al. Eur Respir Rev. 2019 Sep 11;28(153):190029. doi: 10.1183/16000617.0029-2019. Print 2019 Sep 30. Eur Respir Rev. 2019. PMID: 31511255 Free PMC article. Review.

9

Early Recognition and Treatment of Relapsing Polychondritis.

Yanagihara T, Ohgushi M, Setoguchi T, Ogo N, Inutsuka Y, Fujiwara H, Asoh T, Sunami S, Yoneda R, Maeyama T. Yanagihara T, et al. Cureus. 2022 Jan 20;14(1):e21463. doi: 10.7759/cureus.21463. eCollection 2022 Jan. Cureus. 2022. PMID: 35223247 Free PMC article.

10

Insights into Potential Pathogenesis and Treatment Options for Immune-Checkpoint Inhibitor-Related Pneumonitis.

Ando H, Suzuki K, Yanagihara T. Ando H, et al. Among authors: yanagihara t. Biomedicines. 2021 Oct 16;9(10):1484. doi: 10.3390/biomedicines9101484. Biomedicines. 2021. PMID: 34680601 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

59 results

Results by year

Search Page

Filters

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

Search Results

59 results

Results by year